The Risk-Free™ Immune Oncology line of mouse monoclonal and llama single-domain antibodies are developed against functional human recombinant proteins and consist of several unique monoclonal antibodies, allowing a selection of clones for your desired application. Target sets include antibodies developed against PD-1, PD-L1, PD-L2, LAG3, CTLA-4, B7-H3, B7-H4, CD80, CD155, LIGHT, VISTA, and ICOS ligand. Additionally, the antibody line contains high-affinity antibodies against TIGIT (an immune receptor present on T cells and NK cells), TIM-3 (an immunosuppressive protein that enhances tolerance and inhibits antitumor immunity), and TMIGD2 (a novel adhesion molecule expressed in cells of epithelium and endothelium origins). Each antibody is validated and rigorously tested and guaranteed to work for its designated applications. These antibodies are available for research use and diagnostic assay development. Also, they can be licensed for therapeutic development.